Personalizing Chemotherapy

Introduction

In addition to testing for hereditary cancer risk, Myriad Genetic Laboratories is developing new tests for therapeutic and predictive medicine. Results of these tests enable physicians to customize each patient’s chemotherapy and minimize risk for adverse reactions.

OnDose™ is a simple blood test that helps oncologists to optimize infusional 5-FU therapy on an individual basis.

TheraGuide® is a test that predicts 5-FU toxicity and can help you evaluate a patient's risk for serious side effects.

PREZEON™ is a personalized medicine product to assess the status of the PTEN gene.